French contrast developer Guerbet has signed an exclusive agreement with IBM Watson Health to jointly develop artificial intelligence (AI) software for liver cancer diagnostics.
The software will use CT, MRI, and other clinical decision-support tools to advance patient care. The first such software will be called Watson Imaging Care Advisor for Liver. It will be designed to use AI to automate the detection, staging, tracking, monitoring, therapy prediction, and therapy response of primary and secondary liver cancer for clinicians.
The companies plan to design the software so it is compatible with the most common PACS software for integration into the workflows of clinicians and other healthcare professionals.